
Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability.
Will Shrank is CEO of Aradigm Health.

Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability.

Will Shrank, CEO of Aradigm Health, discusses the fragmented payment and delivery system and its impact on cell & gene therapies.